Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 4 of 4 for “"biomarkers of neurodegeneration"”.

  1. Phenotyping Behavioral Disorders in REM Sleep: Study of Digital Biomarkers of Neurodegeneration

    … on advancing the understanding and detection of REM Sleep Behavior Disorder (RBD), a recognized prodromal symptom of alpha-synucleinopathies, among which Parkinson's Disease (PD). By integrating computational approaches with physiological insights, this research presents novel tools and …

    cagliari Repository record for Phenotyping Behavioral Disorders in REM Sleep: Study of Digital Biomarkers of Neurodegeneration (opens in a new tab)

  2. Investigating Pathogenic Mechanisms and Biomarkers in Alzheimer’s Disease

    Alzheimer’s disease (AD) is the most common form of dementia among the elderly and a major public health issue worldwide. Despite decades of research efforts, AD still lacks an effective treatment. Although the first two histopathological markers of AD identified in the 1980’s are brain deposits of

    queens Repository record for Investigating Pathogenic Mechanisms and Biomarkers in Alzheimer’s Disease (opens in a new tab)

  3. Sex Differences in the Relationship Between Physical Activity and Cognitive Health in Ethnically Diverse Older Adults

    … Physical activity (PA) may mitigate the effects of aging on brain health and promote cognition in older adults, with benefits varying by biological sex and ethnicity. Data from the Health and Aging Brain Study – Health Disparities, a community-based cohort of 3585 Hispanic, Non-Hispanic Black …

    calgary Repository record for Sex Differences in the Relationship Between Physical Activity and Cognitive Health in Ethnically Diverse Older Adults (opens in a new tab)

  4. Visual Outcome Measures of Remyelination and Neuroprotection in Multiple Sclerosis

    One of the most tractable ways to delay, prevent or reverse multiple sclerosis (MS) disability progression is by harnessing therapies capable of enhancing endogenous remyelination. Recent trials of remyelination-promoting drugs have marked the beginning of a new phase in the development of

    cambridge Repository record for Visual Outcome Measures of Remyelination and Neuroprotection in Multiple Sclerosis (opens in a new tab)